Last reviewed · How we verify
Trametinib 1.5 MG
At a glance
| Generic name | Trametinib 1.5 MG |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Headache
- Diarrhoea
- Vomiting
- Nausea
- Dry skin
- Cough
- Rash
- Fatigue
- Upper respiratory tract infection
- Neutropenia
- Constipation
Key clinical trials
- Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (PHASE1)
- Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas (PHASE1)
- Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation (PHASE1)
- Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors (PHASE2)
- Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer (PHASE1)
- Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (PHASE1)
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trametinib 1.5 MG CI brief — competitive landscape report
- Trametinib 1.5 MG updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI